MedTrace Logo

Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)

NCT00623779 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2012-03-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and tolerability of AZD0837 in patients with atrial fibrillation who are unable or unwilling to take vitamin K antagonist therapy for up to 3 months.

Conditions

  • Persistent or Permanent Non-valvular Atrial Fibrillation

Interventions

DRUG

AZD0837

ER formulation

DRUG

Aspirin

Oral form

Sponsors & Collaborators

Principal Investigators

  • Gregory Y Lip, MD · Birmingham City Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • Denmark
  • Norway
  • Poland
  • Russia
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00623779 on ClinicalTrials.gov